Bimekizumab infection rates in patients with moderate to severe plaque psoriasis: Analysis of pooled data from 2 years of treatment in phase 3 and 3b clinical trials

Main Article Content

A Armstrong
RG Langley
KB Gordon
RB Warren
D Thaçi
L Stein Gold
L Peterson
C Madden
N Nunez Gomez
D de Cuyper
A Costanzo


bimekizumab, psoriasis, infection, adverse effects, pooled data, clinical trial, safety, phase 3




1. Papp KA et al. J Am Acad Dermatol 2018;79:277–85

2. Warren RB et al. N Engl J Med 2021;385:130–41, NCT03412747 BE SURE

3. Reich K et al. Lancet 2021;397:487–98, NCT03370133 BE VIVID

4. Gordon KB et al. Lancet 2021;397:475–86, NCT03410992 BE READY

5., NCT03598790 BE BRIGHT

6. Reich K et al. N Engl J Med 2021;385:142–52, NCT03536884 BE

Most read articles by the same author(s)

1 2 3 4 > >>